918 F.3d 928
Fed. Cir.2019Background
- Forest Laboratories owns U.S. Patent No. 5,763,476 covering asenapine-containing solid pharmaceutical compositions that “disintegrate within 30 seconds in water at 37°C” and a method claim expressly limited to sublingual or buccal administration (Saphris is sublingual asenapine maleate).
- Multiple generic manufacturers (Sigmapharm, Hikma, Breckenridge, Alembic, Amneal) filed ANDAs seeking to market generic Saphris and were sued by Forest for patent infringement; district court held the asserted claims not invalid and found some defendants did not infringe certain claims.
- Claim 1 recites a solid composition of asenapine that rapidly disintegrates (no express route); claim 4 recites a method of treating various conditions by administering sublingually or buccally.
- The district court construed claim 1 as limited to sublingual/buccal formulations, found claims 1 and 4 non-obvious, found written description adequate, and held Breckenridge and Alembic did not infringe claim 4 (construed to exclude bipolar treatment).
- On appeal, the Federal Circuit affirmed the claim‑construction of claim 1 as limited to sublingual/buccal, vacated and remanded the non‑obviousness determination (for an express finding on one motivation subissue), rejected the unexpected‑results reasoning, affirmed written description, and vacated/remanded the non‑infringement finding for claim 4 (construing “excitation” as a symptom, not a disorder).
Issues
| Issue | Forest’s Argument | Appellants’ Argument | Held |
|---|---|---|---|
| Construction of claim 1: whether the rapid‑disintegrating composition is limited to sublingual/buccal | Claim 1 should be read in view of the specification; the patent repeatedly describes the invention as sublingual or buccal, so claim 1 is so limited | Claim 1’s text lacks an administration limitation; limiting it imports a method step and narrows the claim improperly | Court affirmed the district court: claim 1 is limited to sublingual/buccal formulations based on specification and title |
| Obviousness (motivation to combine) | The inventors discovered unknown cardiotoxicity for oral/as IV routes and sublingual administration solved it; no prior motivation to make sublingual asenapine | Appellants argued motivation existed (e.g., compliance/swallowing issues; more treatment options; prior interest in sublingual forms) and there was expectation of success | Court vacated non‑obviousness and remanded for the district court to make an express finding on whether compliance/swallowing concerns would motivate a skilled artisan to make sublingual/buccal asenapine; rejected unexpected‑results analysis relying on post‑filed knowledge |
| Written description (§112) for asenapine free base in claimed compositions | Specification discloses asenapine free base compositions; skilled artisans would understand inventor possessed claimed subject matter | Appellants argued free base properties made it unsuitable and the spec lacked adequate support | Court held district court’s finding adequate was not clearly erroneous; written description supports claims |
| Infringement of claim 4 (scope as to bipolar/"excitation") | "Excitation" is a symptom; claim 4 covers treating symptoms including excitation (so bipolar I treatment can fall within scope) | District court construed claim 4 to exclude bipolar I disorder and treated "excitation" as a disorder, finding no infringement by Breckenridge and Alembic | Federal Circuit reversed: construed "excitation" as a symptom, vacated non‑infringement and remanded for infringement analysis under corrected construction |
Key Cases Cited
- CardSoft, (Assignment for the Benefit of Creditors), LLC v. VeriFone, Inc., 807 F.3d 1346 (Fed. Cir.) (standard of review for claim construction/factual findings)
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (claims read in view of the specification)
- Markman v. Westview Instruments, Inc., 52 F.3d 967 (Fed. Cir. 1995) (claim construction principles)
- Verizon Servs. Corp. v. Vonage Holdings Corp., 503 F.3d 1295 (Fed. Cir. 2007) (specification can limit claim scope)
- UltimatePointer, L.L.C. v. Nintendo Co., 816 F.3d 816 (Fed. Cir. 2016) (patent title may inform claim construction)
- Arctic Cat Inc. v. Bombardier Recreational Prods. Inc., 876 F.3d 1350 (Fed. Cir. 2017) (motivation to combine is a factual inquiry reviewed for clear error)
- Par Pharm. Inc. v. TWI Pharm., Inc., 773 F.3d 1186 (Fed. Cir. 2014) (obviousness review after bench trial)
- Smiths Indus. Med. Sys., Inc. v. Vital Signs, Inc., 183 F.3d 1347 (Fed. Cir. 1999) (need for reason, suggestion, or motivation to combine references)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (motivation to combine and common sense in obviousness analysis)
- Leo Pharm. Prods., Ltd. v. Rea, 726 F.3d 1346 (Fed. Cir. 2013) (unknown problem in the art can weigh against obviousness)
- WBIP, LLC v. Kohler Co., 829 F.3d 1317 (Fed. Cir. 2016) (long‑felt need supports non‑obviousness)
- Bristol‑Myers Squibb Co. v. Teva Pharm. USA, Inc., 752 F.3d 967 (Fed. Cir. 2014) (long‑felt need is factual)
- United States v. Adams, 383 U.S. 39 (1966) (unexpected results support non‑obviousness)
- In re Soni, 54 F.3d 746 (Fed. Cir. 1995) (unexpected results must be surprising to skilled artisan at time of invention)
- Knoll Pharm. Co. v. Teva Pharm. USA, Inc., 367 F.3d 1381 (Fed. Cir. 2004) (post‑filed evidence may be considered for unexpected results under limits)
- In re Geisler, 116 F.3d 1465 (Fed. Cir. 1997) (timing for whether results were unexpected)
- Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (written description legal standard)
- Pozen Inc. v. Par Pharm., Inc., 696 F.3d 1151 (Fed. Cir. 2012) (written description reviewed for clear error)